Supernitro
Acute Pulmonary Hypertension (aPH), post-cardiac surgery
Phase 2Active
Key Facts
Indication
Acute Pulmonary Hypertension (aPH), post-cardiac surgery
Phase
Phase 2
Status
Active
Company
About AttgeNO
Attgeno is a clinical-stage biotech leveraging a proprietary nitric oxide-donating platform to develop targeted therapies for acute pulmonary hypertension and other conditions. The company has recently completed a Phase IIa study for its lead candidate, Supernitro, in post-cardiac surgery aPH patients. Its leadership team includes world-renowned NO experts and veterans from successful companies like Aerocrine and Actelion, providing deep experience in both the science and commercialization of pulmonary hypertension treatments.
View full company profile